Dr. Hui Zhang is a professor of pathology at Johns Hopkins University and the director of the Johns Hopkins Mass Spectrometry Core Facility and the Center for Biomarker Discovery and Translation. Dr. Zhang specializes in proteomics, and she studies protein modifications on the proteome scale and the effects of protein modifications on protein functions and diseases. She is the inventor of the famous N-Glycosylation proteomics pipeline. For the past few years, her laboratory has further developed several novel glycoproteomic and glycomic technologies to study structures of cell surface glycoproteins and secreted glycoproteins. Currently, researchers in her group focus on understanding the functions of protein modifications in biology and human diseases.
Dr. Zhang’s laboratory is one of the three founding laboratory members of the Clinical Proteomic Tumor Analysis Consortium (CPTAC), and the other two members are the Broad Institute in the State of Massachusetts and the Pacific Northwest National Laboratory in the State of Washington. CPTAC is organized under NIH and NCI in the USA, and it represents the national commitment to fostering clinical proteomics discoveries and applications by the US government. Research papers published by Dr. Zhang and her colleagues in CPTAC represent the gold standard for clinical proteomics researches and the best knowledge of human beings on cancer-related clinical proteomics. Three typical examples of her pioneer works in CPTAC are as follows:
- Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. Cell. 2016 Jul 28;166(3):755-765.
- Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell. 2019 Oct 31;179(4):964-983.e31.
- Proteogenomic characterization of pancreatic ductal adenocarcinoma.Cell. 2021 Sep 16;184(19):5031-5052.e26.
In recent years, in addition to her contribution to the CPTAC project, Dr. Zhang has published her clinical proteomics works repeatedly on top profile journals, including Cell, Nature, Nature Biotechnology, Nature Protocols, Cancer Cell, PNAS, etc. Dr. Zhang’s clinical proteomics discoveries have been cited close to 20,000 times.
Disclaimer: Required by the Agreement with Johns Hopkins University, we wish to disclaim that participation by Dr. Hui Zhang as a Scientific Advisor to Complete Omics Inc. does not constitute or imply endorsement of Complete Omics Inc. by Johns Hopkins University.